Free Press Journal

New compound shrinks pancreatic cancer tumours


London : Scientists have designed a new chemical compound that has reduced the growth of pancreatic cancer tumours by 80 per cent in treated mice, reports PTI.

The compound, called MM41, was designed to block faulty genes by targeting little knots in the DNA, called quadruplexes, which are very different from normal DNA and which are especially found in faulty genes.

The findings showed that MM41 had a strong inhibiting effect on two genes – k-RAS and BCL-2 – both of which are found in the majority of pancreatic cancers. Researchers at the University College London (UCL), led by professor Stephen Neidle, conducted a small-scale trial, treating two groups of eight mice with pancreatic tumours with different doses of MM41 twice a week for 40 days (12 doses). A further control group received no treatment.

The tumours in the group given the larger dose decreased by an average of 80 per cent during the treatment period, and after 30 days, tumour regrowth stopped in all the mice. For two of the mice in this group, the tumour disappeared completely with no signs of regrowth after treatment ended for a further 239 days (the approximate equivalent to the rest of their natural life span).

Analysis of the mice tumours showed that the MM41 compound had been taken up into the nucleus of the cancer cells showing that it was able to effectively target the pancreatic cancer tumour. The team also saw no significant side effects on the mice during the study: there was no damage to other tissue or organs, and none of the mice showed any significant weight loss.

“This research provides a potentially very powerful alternative approach to the way that conventional drugs tackle pancreatic cancer, by targeting a very specific area of the DNA of faulty genes,” said Neidle.